WO2008010083A3 - Method for prognosing osteoporosis phenotypes - Google Patents

Method for prognosing osteoporosis phenotypes Download PDF

Info

Publication number
WO2008010083A3
WO2008010083A3 PCT/IB2007/002363 IB2007002363W WO2008010083A3 WO 2008010083 A3 WO2008010083 A3 WO 2008010083A3 IB 2007002363 W IB2007002363 W IB 2007002363W WO 2008010083 A3 WO2008010083 A3 WO 2008010083A3
Authority
WO
WIPO (PCT)
Prior art keywords
osteoporosis
prognosing
phenotypes
osteoporosis phenotypes
variables
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/002363
Other languages
French (fr)
Other versions
WO2008010083A2 (en
Inventor
Ainara Cadaval
Hernandez Diego Tejedor
Martinez Antonio Martinez
Buela Laureano Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progenika Biopharma SA
Original Assignee
Progenika Biopharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613843A external-priority patent/GB0613843D0/en
Priority claimed from GB0623502A external-priority patent/GB0623502D0/en
Application filed by Progenika Biopharma SA filed Critical Progenika Biopharma SA
Priority to CA002657478A priority Critical patent/CA2657478A1/en
Priority to EP07789643A priority patent/EP2049685A2/en
Priority to JP2009519000A priority patent/JP2009542248A/en
Priority to AU2007274720A priority patent/AU2007274720B2/en
Priority to US12/309,162 priority patent/US8296073B2/en
Publication of WO2008010083A2 publication Critical patent/WO2008010083A2/en
Publication of WO2008010083A3 publication Critical patent/WO2008010083A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method for prognosing osteoporosis phenotypes or estimating osteoporosis quantitative traits comprising determining outcomes for selected SNP variables and clinical variables. Products and methods for genotyping multiple osteoporosis associated genetic variations.
PCT/IB2007/002363 2006-07-12 2007-07-12 Method for prognosing osteoporosis phenotypes Ceased WO2008010083A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002657478A CA2657478A1 (en) 2006-07-12 2007-07-12 Diagnostic method
EP07789643A EP2049685A2 (en) 2006-07-12 2007-07-12 Method for prognosing osteoporosis phenotypes
JP2009519000A JP2009542248A (en) 2006-07-12 2007-07-12 Diagnosis method
AU2007274720A AU2007274720B2 (en) 2006-07-12 2007-07-12 Method for prognosing osteoporosis phenotypes
US12/309,162 US8296073B2 (en) 2006-07-12 2007-07-12 Diagnostic method

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0613843A GB0613843D0 (en) 2006-07-12 2006-07-12 Methods and products for in vitro genotyping
GB0613843.2 2006-07-12
GB0623502.2 2006-11-24
GB0623502A GB0623502D0 (en) 2006-11-24 2006-11-24 Diagnostic method

Publications (2)

Publication Number Publication Date
WO2008010083A2 WO2008010083A2 (en) 2008-01-24
WO2008010083A3 true WO2008010083A3 (en) 2008-07-17

Family

ID=38957149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002363 Ceased WO2008010083A2 (en) 2006-07-12 2007-07-12 Method for prognosing osteoporosis phenotypes

Country Status (6)

Country Link
US (1) US8296073B2 (en)
EP (1) EP2049685A2 (en)
JP (1) JP2009542248A (en)
AU (1) AU2007274720B2 (en)
CA (1) CA2657478A1 (en)
WO (1) WO2008010083A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153363B2 (en) 2005-01-13 2012-04-10 Progenika Biopharma S.A. Methods and products for in vitro genotyping
WO2010083294A2 (en) * 2009-01-16 2010-07-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for osteoporosis
MD4151C1 (en) * 2010-01-19 2012-09-30 ШКИЛЁВ Думитру Method for the application of the individual identification tag and individual identification tag
JP2013097693A (en) * 2011-11-04 2013-05-20 Hitachi Solutions Ltd Osteoporosis risk determination system and program
US10207027B2 (en) 2012-06-11 2019-02-19 Globus Medical, Inc. Bioactive bone graft substitutes
CN106897579A (en) * 2015-12-19 2017-06-27 中国人民解放军北京军区总医院 New early tumor markers based on chromosomal variation index and its application
CN110021429A (en) * 2019-03-04 2019-07-16 北京大学人民医院(北京大学第二临床医学院) Ankle-joint surrounding fracture clinic intelligent decision support system

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027321A1 (en) * 1996-01-25 1997-07-31 Universite Laval Marker at the estrogen receptor gene for determination of osteoporosis predisposition
WO2000015836A2 (en) * 1998-09-15 2000-03-23 Signalgene Inc. Combination of markers at the estrogen- and vitamin d-receptor genes or equivalents thereof to prognose a response to osteoporosis therapy
WO2003066903A2 (en) * 2002-02-06 2003-08-14 The University Court Of The University Of Aberdeen Genetic markers for bone mass
WO2004046381A1 (en) * 2002-11-21 2004-06-03 The University Court Of The University Of Aberdeen Polymorphisms in th clcn7 gene as genetic markers for bone mass
WO2004097044A1 (en) * 2003-04-29 2004-11-11 Oxagen Limited Method of diagnosins a genetic susceptibility for bone damage
US20060057612A1 (en) * 2000-09-14 2006-03-16 Unnur Styrkarsdottir Methods for diagnosing osteoporosis or a susceptibility to osteoporosis based on haplotype association

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825336B1 (en) * 2000-09-08 2004-11-30 Applera Corporation Polymorphisms in known genes associated with osteoporosis, methods of detection and uses thereof
US20090307179A1 (en) * 2008-03-19 2009-12-10 Brandon Colby Genetic analysis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027321A1 (en) * 1996-01-25 1997-07-31 Universite Laval Marker at the estrogen receptor gene for determination of osteoporosis predisposition
WO2000015836A2 (en) * 1998-09-15 2000-03-23 Signalgene Inc. Combination of markers at the estrogen- and vitamin d-receptor genes or equivalents thereof to prognose a response to osteoporosis therapy
US20060057612A1 (en) * 2000-09-14 2006-03-16 Unnur Styrkarsdottir Methods for diagnosing osteoporosis or a susceptibility to osteoporosis based on haplotype association
WO2003066903A2 (en) * 2002-02-06 2003-08-14 The University Court Of The University Of Aberdeen Genetic markers for bone mass
WO2004046381A1 (en) * 2002-11-21 2004-06-03 The University Court Of The University Of Aberdeen Polymorphisms in th clcn7 gene as genetic markers for bone mass
WO2004097044A1 (en) * 2003-04-29 2004-11-11 Oxagen Limited Method of diagnosins a genetic susceptibility for bone damage

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GENNARI L ET AL: "Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a HuGE review", AMERICAN JOURNAL OF EPIDEMIOLOGY, SCHOOL OF HYGIENE & PUBLIC HEALTH OF THE JOHNS, US, vol. 161, no. 4, 15 February 2005 (2005-02-15), pages 307 - 320, XP002357226, ISSN: 0002-9262 *
HOSOI T. ET AL.,: "association study of parathyroid hormone gene polymorphism and bone density in japanese postmenopausal women", CALCIF. TISSUE INT., vol. 64, 1999, pages 205 - 208, XP002476933 *
IOANNIDIS J.P.A. ET AL.,: "Differential gentic effects of the ESR1 gen polymorphisms on osteoporosis outcomes", JAMA, vol. 292, no. 17, 3 November 2004 (2004-11-03), pages 2105 - 2114, XP002466770 *
KATSUMATA K. ET AL.,: "association of gene polymorphisms and bone density in japanese girls", J BONE MINER METAB, vol. 20, 2002, pages 164 - 169, XP002476934 *
KOBAYASHI S ET AL: "ASSOCIATION OF BONE MINERAL DENSITY WITH POLYMORPHISM OF THE ESTROGEN RECEPTOR GENE", JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 11, no. 3, 1 March 1996 (1996-03-01), pages 306 - 311, XP000671392, ISSN: 0884-0431 *
SHIELDS J.J. ET AL.,: "DraII and XmnI polymorphisms at the human parathyroid hormone locus", NUCLEIC ACID RESEARCH, vol. 19, no. 15, 1992, pages 4312 - 4312, XP002476932 *

Also Published As

Publication number Publication date
US8296073B2 (en) 2012-10-23
CA2657478A1 (en) 2008-01-24
EP2049685A2 (en) 2009-04-22
US20100069334A1 (en) 2010-03-18
WO2008010083A2 (en) 2008-01-24
AU2007274720A1 (en) 2008-01-24
JP2009542248A (en) 2009-12-03
AU2007274720B2 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
WO2008010083A3 (en) Method for prognosing osteoporosis phenotypes
WO2009059317A3 (en) Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
GB2435534B (en) Method,system,and computer program product for performing prognosis and asset management services
IL211140A (en) Method of determining risk of alzheimer's disease based on the presence or absence of variants in the tomm40 gene
PL2121963T3 (en) Methods for identifying a strain isolated from a clinical sample at the species and/or subspecies level
WO2010001419A3 (en) Copy number variations predictive of risk of schizophrenia
DE602007011545D1 (en) Automatic system for performing localized inventories
WO2010002883A3 (en) Methods and devices for single-molecule whole genome analysis
WO2009148528A8 (en) Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment
WO2008106579A3 (en) The role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
WO2012170725A3 (en) Materials and method for identifying spinal muscular atrophy carriers
WO2009049916A3 (en) Method for determining methylation at cytosine residues
EP2345963A4 (en) Computer system, method, and computer program for managing batch job
AP3018A (en) Compositions and methods for inhibiting expressionof a gene from the ebola
WO2008135986A3 (en) System, method and device for comprehensive individualized genetic information or genetic counseling
DK2061910T3 (en) Procedure for forecasting
WO2008103299A8 (en) Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
WO2008042771A3 (en) System and method for developing and managing a manufacturing process
WO2009097270A3 (en) Method of determining breast cancer risk
WO2007140599A8 (en) Assessment of risk for colorectal cancer
WO2007086980A3 (en) Methods of determining the risk of developing coronary artery disease
EP2195463A4 (en) Method for identifying the sequence of one or more variant nucleotides in a nucleic acid molecule
WO2011020075A3 (en) Amelogenin snp on chromosome x
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
WO2009117346A3 (en) System and method for determining the health of a subject using polymorphic risk markers

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2009519000

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2657478

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007789643

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007274720

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2007274720

Country of ref document: AU

Date of ref document: 20070712

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12309162

Country of ref document: US